Enfuvirtide-acetaat (T-20)
Alias:Fuzeon
Reeks:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No. : 159519-65-0
Moleculaire formule : C204H301N51O64
Molecuulgewicht : 4492
Zuiverheid (HPLC) : 98.0%min.
Uiterlijk : Witte tot gebroken witte amorfe vaste stof
Enkele onzuiverheid (HPLC) : 0.5%max
Aminozuursamenstelling : ±10% van theoretisch
Peptide-inhoud (N%) : ≥80,0%
Water inhoud (Karl Fischer) : ≤8.0%
Trifluoracetaat inhoud(HPIC) : ≤12,0%
MEVROUW (ESI) : Consequent
Massabalans : 95.0~105,0%
Cijfer : Farmaceutische kwaliteit:
Opslag: Gesloten, onderstaand 2 ~ 8℃ behoud
Gebruik : Behandelingsoptie voor patiënten die lijden aan hiv/aids.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (CAFE) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
